Welcome To Diurnal

Diurnal is a UK-based specialty pharmaceutical company dedicated to developing high-quality hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia, Adrenal Insufficiency, Hypogonadism and Hypothyroidism.

The company has a strong, multi-skilled entrepreneurial management team with extensive pharmaceutical product development experience and an affiliated network of world-class clinical experts in the area of endocrinology.

Mission Statement

To address the major unmet clinical and patient needs in endocrinology by creating high quality products for the lifelong treatment of chronic conditions.

Latest News

  • 09 May
    2019

    Intent to Submit for Market Authorisation Application for Chronocort® tendered to the EMA

    Diurnal on track to submit Market Authorisation Application in Europe in Q4 2019

    Read More

  • 24 Apr
    2019

    Alkindi® granted Orphan Drug Designation in Australia and grant of second Alkindi® patent in Australia

    Significant opportunity to address unmet medical need in paediatric adrenal insufficiency in Australia  

    Read More

  • 11 Apr
    2019

    Positive Scientific Advice from European Medicines Agency for Chronocort®

    European Medicines Agency confirms the current clinical and regulatory path for Chronocort® .Diurnal on track to submit Market Authorisation Application in Q4 2019

    Read More